Faeth Therapeutics has raised $25 million in funding led by S2G Ventures, bringing total capital raised to $92 million. Participating investors include Khosla Ventures, Future Ventures, Digitalis Ventures, KdT Ventures, Cantos, B Capital Group, Avicella, and THO Seed Fund.
The Austin-based company develops therapies targeting tumor metabolism through multi-node inhibition of the PI3K/AKT/mTOR pathway. The funding will advance a phase 2 endometrial cancer program through data readout in Q3 2026, expand the company’s MetabOS platform, support a phase 1 study in locally advanced rectal cancer, and fund work toward a Q4 2026 clinical entry for Hereditary Tyrosinemia Type 1, a rare pediatric metabolic disorder.
Faeth also presented results from two cancer trials at the European Society for Medical Oncology Congress 2025 in Barcelona. In endometrial cancer, a phase 1b study of serabelisib plus sapanisertib with paclitaxel achieved an 80% overall response rate with median progression-free survival of 11 months. The Gynecologic Oncology Group Foundation has initiated a phase 2 trial, now enrolling patients.
The DICE trial in platinum-resistant ovarian cancer enrolled 134 patients across sites in the United Kingdom and Germany. The combination of sapanisertib plus weekly paclitaxel achieved mean progression-free survival of 5.8 months compared to 4.0 months with paclitaxel alone. Grade 3/4 adverse events occurred in 7% of patients receiving the combination versus 6.6% for paclitaxel alone.
“Platinum-resistant ovarian cancer remains one of the toughest conditions we face, with women often cycling through treatments that only briefly hold the disease at bay temporarily,” said Jonathan Krell, MD, Ovarian Cancer Action Research Centre, Imperial College London, the study’s lead investigator. “The DICE trial shows that adding an oral targeted agent to weekly paclitaxel can slow progression without added high-grade toxicity, a finding that clearly warrants a phase 3 trial.”
“We’ve achieved the optimal balance in PI3K pathway inhibition, comprehensive enough to prevent resistance, selective enough to avoid immunosuppression,” said Anand Parikh, CEO of Faeth Therapeutics. “The 80% response rate, 11-month progression-free survival, initiation of a trial by the GOG Foundation, and recognition as a late-breaking oral presentation at ESMO show that Faeth is executing as a clinical-stage company positioned to expand across the solid tumors where PI3K alterations drive disease.”
The DICE trial met its prespecified hazard ratio target of 0.66, supporting advancement to phase 3. Faeth Therapeutics was founded in 2019 by Lewis Cantley, PhD, Siddhartha Mukherjee, MD, DPhil, Karen Vousden, PhD, Scott Lowe, PhD, and Greg Hannon, PhD.
